Ribosome Inhibitors
1 drugsAbout Ribosome
The ribosome is a complex molecular machine in all living cells responsible for protein synthesis, translating genetic code into functional proteins essential for cellular processes.
The ribosome's fundamental role in protein production makes it a compelling therapeutic target, though currently there is no genetic evidence directly linking it to specific diseases.
There is one FDA-approved drug, ARIKAYCE KIT, targeting the ribosome; it is a small molecule with 9 indications and falls under the 'Other' therapeutic area.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Ventilator Associated Pneumonia ( VAP) with only 1 trials.
Top Drugs
INSMED INC is the only company with an approved drug targeting the ribosome.
Low competition suggests high barriers to entry or untapped potential in targeting the ribosome.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Ribosome, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel approaches like biologics.
Clinical Trials 41 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 10 | 0 | 1 | 100% |
| Phase 2 | 12 | 5 | 3 | 4 | 63% |
| Phase 3 | 7 | 6 | 0 | 1 | 100% |
| Phase 4 | 10 | 7 | 2 | 1 | 78% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2018 - 2018)
The first and most recent drug approval was ARIKAYCE KIT in 2018.
The single approval indicates a potentially unsaturated market with room for new ribosome-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 23 clinical trials targeting Ribosome.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities